COVID-19 drug trial halted early: only 16 patients enrolled

NCT ID NCT04880109

Terminated Disease control Sponsor: Aptabio Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested an experimental drug called APX-115 in hospitalized patients with mild to moderate COVID-19. The goal was to see if it was safe and could help people recover faster. However, the trial was stopped early and only 16 people took part, so we don't have enough information to know if the drug works or is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APX-115 (oral capsule)
What this could lead to: If it worked, APX-115 could offer a new oral treatment option for mild to moderate COVID-19, potentially speeding recovery.
What could go wrong: The trial was terminated early with only 16 participants, far short of the planned 80. This means results are very limited and no conclusions can be drawn about effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Anne Arundel Medical Center

Annapolis, Maryland, 21401, United States
FASN, FAHA; John L. McClellan Memorial Veterans Hospital

Little Rock, Arkansas, 72205, United States
FCCP; Jamaica Hospital Medical Center

Jamaica, New York, 11418, United States
MSc, FAAN; Metro Health Hospital - Professional Building

Wyoming, Michigan, 49519, United States
Medical City Fort Worth

Fort Worth, Texas, 76104, United States
TriHealth Bethesda North Hospital

Cincinnati, Ohio, 45242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.